Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldara in plaque-type morphea
NCT00230373Phase 3Withdrawn
- Sponsor
- University of Alberta
- Start
- Nov 2005
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label trial of imiquimod in morphea, sponsored by University of Alberta. Primary endpoint: Percent improvement in skin induration at 12 months. Planned start Nov 2005; status: withdrawn.
02
Drugs
imiquimod
03
Conditions
morphea
Beyond the preview
Go deeper on NCT00230373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00230373.